Definitive Contract HHSD200200929373C
Award Date 4/1/09
Potential Completion Date 3/31/10
Potential Value $15B
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $21,494,073,684.68 Definitive, Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Pfizer Inc. (Wyeth Division) for a pediatric vaccine program. The contract has an ultimate completion date of March 31, 2011 and was not set aside. This contract appears to be part of the CDC's Vaccines for Children (VFC) program, which provides vaccines at no cost to children who might not otherwise be vaccinated because of...
- This is a definitive, firm fixed-price contract awarded by the CDC Office of Acquisition Services, a civilian agency, to Glaxosmithkline Holdings (Americas) Inc. on April 1, 2009. The contract, valued at $13,015,897,209.20, is for the provision of pediatric vaccines under the Vaccines for Children (VFC) program. The contract has a period of performance through March 31, 2010 and does not have a set-aside designation. As the prime contractor, Glaxosmithkline Holdings (Americas) Inc. will be...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed price Definitive Contract to Pfizer Inc., a large pharmaceutical company, for the 2017 Vaccines for Children program. The contract has a potential value of $1,347,249,175.05 and a completion date of March 31, 2018. The contract does not have a set-aside designation. Under this award, Pfizer will provide a variety of pharmaceutical products and vaccines to support immunization programs...
- This is a definitive contract awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Merck Sharp & Dohme Corp. for the "MERCK PEDIATRIC VACCINE CONTRACT". The contract has a firm fixed price pricing type and a ceiling value of $39,055,333,994.98. The period of performance is from April 1, 2010 to March 31, 2011, and the place of performance is West Point, Pennsylvania. This contract was not set aside for any specific business category. The...
- This is a definitive, firm fixed-price contract awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services to Novartis Vaccines and Diagnostics, Inc., a foreign-owned for-profit organization. The contract, valued at $3,998,636,358.75, is for the TAS 00HCVGBC-2010-82345 - Novartis Pediatric Vaccine Contract and does not have a set-aside designation. The contract has an ultimate completion date of March 31, 2011. As a pediatric vaccine contract, this award...
- This is a firm fixed-price definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc. for the supply of adult vaccines. The contract has a ceiling value of $54,499,343.31 and an ultimate completion date of June 30, 2016. The contract does not have a set-aside designation. Pfizer, the prime contractor, is a global pharmaceutical corporation that plays a significant role in supplying medical products and services to the U.S. federal government. This contract...
- This is a $41,402,500.00 firm fixed price definitive contract awarded to Pfizer Inc. (Pfizer) by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) for the provision of adult vaccines. The contract has a performance period ending on June 30, 2018, with no set-aside designation mentioned. As the prime contractor, Pfizer will be directly delivering the vaccines without the involvement of major subcontractors. The vaccines to be supplied include those for...
- This is a $6,859,517,906.00 firm fixed-price definitive contract awarded by the Bureau for Global Health, a civilian agency within the U.S. government, to Pfizer Inc. for the provision of COVID-19 vaccines for international donation. The contract has an ultimate completion date of February 29, 2024 and does not utilize any set-aside designations. Pfizer is the prime contractor for this award, which is associated with the company's existing Vaccines for Children (VFC) program contract with the...
- This is a $8,650,565,549.53 Firm Fixed Price definitive contract awarded to Pfizer Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) for the provision of COVID-19 vaccines. The contract has an ultimate completion date of May 29, 2024 and was awarded on October 1, 2022 without any set-aside designation. Pfizer, a global pharmaceutical manufacturer, is the prime contractor for this award. The contract supports the government's COVID-19 vaccine initiatives and is...
- This $2,299,932.44 firm-fixed-price contract was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc. for the storage and rotation of Pfizer's COVID-19 vaccine. The contract has an ultimate completion date of July 31, 2022 and was awarded on August 1, 2017. The contract does not have a set-aside designation. Pfizer, a large global pharmaceutical corporation, is the prime contractor for this award. The contract is part of a larger Indefinite Delivery Vehicle (IDV) that...